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Abstract
Background: The oldest-old (subjects aged 90 years and older) population represents the fastest growing segment
of society and shows a high dementia prevalence rate of up to 40%. Only a few studies have investigated protective
factors for cognitive impairment in the oldest-old. The EMIF-AD 90+ Study aims to identify factors associated with
resilience to cognitive impairment in the oldest-old. In this paper we reviewed previous studies on cognitive resilience
in the oldest-old and described the design of the EMIF-AD 90+ Study.
Methods: The EMIF-AD 90+ Study aimed to enroll 80 cognitively normal subjects and 40 subjects with cognitive
impairment aged 90 years or older. Cognitive impairment was operationalized as amnestic mild cognitive impairment
(aMCI), or possible or probable Alzheimer’s Disease (AD). The study was part of the European Medical Information
Framework for AD (EMIF-AD) and was conducted at the Amsterdam University Medical Centers (UMC) and at the
University of Manchester. We will test whether cognitive resilience is associated with cognitive reserve, vascular
comorbidities, mood, sleep, sensory system capacity, physical performance and capacity, genetic risk factors, hallmarks
of ageing, and markers of neurodegeneration. Markers of neurodegeneration included an amyloid positron emission
tomography, amyloid β and tau in cerebrospinal fluid/blood and neurophysiological measures.
Discussion: The EMIF-AD 90+ Study will extend our knowledge on resilience to cognitive impairment in the oldest-old
by extensive phenotyping of the subjects and the measurement of a wide range of potential protective factors,
hallmarks of aging and markers of neurodegeneration.
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The oldest-old (subjects aged 90 years and older) popu-
lation represents the fastest growing segment of society
[1]. Worldwide, the number of oldest-old subjects is ex-
pected to increase to 71.2 million in 2050, a 5-fold in-
crease of the current oldest-old population [2, 3]. The
oldest-old have a high risk of developing dementia with
a prevalence up to 40% [4]. The increasing number of
oldest-old subjects with dementia will have major clin-
ical and financial consequences for patients, their fam-
ilies and society as a whole [5].
Still a considerable number of subjects remain cogni-
tively normal at high age, indicating the presence of pro-
tective factors for cognitive impairment in these
subjects. Identification of these protective factors is cru-
cial and will have implications for preventive strategies.
In addition, identifying the neurodegenerative markers
associated with cognitive impairment in the oldest-old,
will enhance our understanding of the underlying patho-
physiology in this specific age group.
The EMIF-AD 90+ study was set-up to investigate
protective factors for cognitive impairment in the
oldest-old. We will first provide an overview of the
current status of research on this topic and then present
the study outline of the EMIF-AD 90+ study.
Review on studies on cognitive impairment in the oldest-old
We searched for studies focusing on protective factors for
cognitive impairment in nonagenarians, which gave us
two results: The 90+ Study in the USA and the Danish
Birth Cohort Studies [6, 7]. Broadening the search to stud-
ies that started inclusion from the age of 85 years or fo-
cused on successful aging resulted in eight more studies:
the H85 Gothenburg study, Leiden 85-plus Study, New-
castle 85+ Study, NonaSantfeliu study, Octabaix study,
Project of Longevity and Aging in Dujangyan (PLAD),
Umeå study and Vantaa 85+ Study [8–15]. Table 1 shows
the design characteristics of these ten studies.
Protective factors for cognitive impairment in the oldest-old
Table 2 summarizes the findings on the protective fac-
tors for cognitive impairment or dementia of the ten
studies. A high level of education was found to be pro-
tective against dementia in the oldest-old and one study
indicated that high cognitive activity, examined by look-
ing at the time spend on reading, around age 90 years
was related to resilience to dementia [4, 16–18]. The in-
fluence of vascular comorbidities on cognition has been
studied quite extensively in this age group. Most studies
did not find an association between cholesterol levels
and cognition in the oldest-old [15, 17, 19–22]. Hyper-
tension has mostly been found to be protective in the
oldest-old, especially when hypertension is diagnosed
after the age of 80 years [17, 19, 23–27]. This is in con-
trast to studies that have shown a higher dementia risk
in the presence of midlife hypertension [28]. In addition,
although midlife diabetes mellitus has been related to
dementia in younger subjects [29], the influence of dia-
betes mellitus on cognition might be less evident in the
oldest-old [11, 30, 31]. The protective effect related to
the absence of stroke seemed to persist in the oldest-old
[18, 32] and one study on atrial fibrillation and dementia
did not find an association [32]. The absence of depres-
sive symptoms seemed to be associated with resilience
to cognitive impairment, which is consistent with find-
ings in younger subjects [14, 33, 34]. One study related
sleep quality to cognition and reported a higher sleep
quality in subjects without cognitive impairment, which
is in line with results in younger subjects [35, 36]. With
regard to the sensory system, visual and auditory impair-
ments have been associated with worse cognitive func-
tioning in the oldest-old [37, 38] and although olfactory
impairment has been associated with incident dementia
in a younger age group [39], no studies were found
studying this in the oldest-old.
Data about physical performance and activity have been
collected in the Leiden 85-plus study and The 90+ Study.
Good physical performance, measured with handgrip
strength, 4 m walk or standing balance tests, was associ-
ated with better cognitive functioning and lower dementia
incidence in the oldest-old but high physical activity did
not seem to influence dementia incidence [16, 40, 41].
With regard to genetics, the Apolipoprotein E (APOE)
genotype, a major risk factor for AD in younger subjects,
has been extensively studied in the oldest-old, with mixed
results regarding the relation to cognition and dementia
[42–46]. The Danish 1905 birth cohort, PLAD and Vantaa
85+ Study also studied a number of other genotypes in
the oldest-old and found some additional protective and
risk genotypes which are described in Table 2.
Hallmarks of aging and cognition in the oldest-old
Hallmarks of aging [47], such as inflammation and cellu-
lar senescence [48], have been scarcely studied in rela-
tion to cognition in the oldest-old. The Leiden 85-plus
Study and The 90+ Study related inflammation markers
to cognition and dementia but showed mixed results
[49–51]. In addition, telomere length measured in white
blood cells were not associated with cognition, dementia
prevalence or incident dementia [52].
Markers of neurodegeneration and cognition in the oldest-old
Limited information is available about the relation of
markers of neurodegeneration, such as amyloid β and
tau measured in cerebrospinal fluid (CSF) and/or with a
positron emission tomography (PET) scan with cognitive
impairment in the oldest-old. Postmortem studies have
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Table 2 Potential protective factors for cognitive impairment in the oldest-old
Domain Potential protective
factor
Study Agea Sample size (N) Outcome
variable
Result
Cognitive reserve High level of education H85 Gothenburg
study [18]
85.7 (±0.05) No dementia: 794
Dementia: 271
Dementia Protective
The 90+ Study [4] 94 (90–106) No dementia: 536
Dementia: 375
Dementia Protective































94.3 (±2.6) 62, dementia status
unknown
Cognition No effect
Octabaix study [22] 85 (85) 321, dementia status
unknown
Cognition No effect

























































Absence of DM Leiden 85-plus Study
[30]
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Table 2 Potential protective factors for cognitive impairment in the oldest-old (Continued)
Domain Potential protective
factor
Study Agea Sample size (N) Outcome
variable
Result
Absence of stroke H85 Gothenburg
study [18]
85.7 (±0.05) No dementia: 794
Dementia: 271
Dementia Protective














Mood and sleep No depression Leiden 85-plus Study
[34]
85 (85) 500, dementia status
unknown
Cognition Protective



















85 (85) No dementia: 771
Dementia: 68
Cognition Protective




















85 (85) 555, dementia status
unknown
Cognition Protective

























89.0 (87.4–91.2)b No dementia: 242
Dementia: 78
Dementia Protective







Vantaa 85+ Study [45] ≥85 313 without dementia
197 with dementia
Dementia Protective
















ACOX1 Danish 1905 birth
cohort [106]
93.2 (92.7–93.8) 1089, dementia status
unknown
Cognition Risk








MTHFR, MTR Danish 1905 birth
cohort [111]
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shown that the prevalence of amyloid aggregation in-
creases with age in cognitively healthy subjects but de-
creases in the oldest-old subjects with dementia [1]. A
similar trend can be seen with regard to amyloid β mea-
sured in CSF or on an amyloid PET scan [53, 54]. In
subjects without dementia, greater amyloid load has
been associated with poorer cognitive functioning and a
higher rate of incident dementia, although the number
of oldest-old subjects in these studies was limited [55–
57]. There are a few studies that have related brain MRI
measurements in the oldest-old to cognitive functioning.
Less atrophy and fewer white matter hyperintensities were
seen in subjects without dementia compared to subjects
with dementia [58, 59] but white matter integrity was not
related to cognition [60]. In younger subjects, neuro-
physiological measures on magnetoencephalography
(MEG) have been related to dementia [61] but it is un-
known whether this relationship persists in the oldest-old.
Aims and objectives of the EMIF-AD 90+ study
The EMIF-AD 90+ Study was set-up to investigate the pro-
tective factors for cognitive impairment in the oldest-old.
The study was part of the Innovative Medicine Initiative
(IMI) European Medical Information Framework for AD
(EMIF-AD) project (http://www.emif.eu/about/emif-ad) on
diagnostic markers, prognostic markers, and protective fac-
tors for AD. The EMIF-AD 90+ study focuses on the ex-
treme phenotype of the cognitively normal oldest-old. The
primary objectives of the EMIF-AD 90+ study are:
i) To identify factors associated with resilience to
cognitive impairment in the oldest-old.
Table 2 Potential protective factors for cognitive impairment in the oldest-old (Continued)
Domain Potential protective
factor
Study Agea Sample size (N) Outcome
variable
Result










LRP, LPL, ACE Vantaa 85+ Study
[114]
≥85 No dementia: 203
Dementia (AD): 113
Dementia No effect








The 90+ Study [50] 94.3 (90–105) No dementia: 232
Dementia: 73
Dementia Equivocal







































Less brain atrophy H85 Gothenburg
study [58]
85 (85) No dementia: 30
Dementia: 23
Dementia Equivocal
Less WMH H85 Gothenburg
study [59]





The 90+ Study [60] 94.6 (90–103) Normal: 64
CIND: 30
CIND No effect
Aβ Amyloid β, AD Alzheimer’s disease, APOE Apolipoprotein E, CIND Cognitive Impairment, No Dementia, CSF cerebrospinal fluid, DM diabetes mellitus, HDL high-density
lipoproteins, LDL low-density lipoproteins, MCI Mild Cognitive Impairment, MMSE Mini-Mental State Examination, N Number, PET positron emission tomography, PLAD
Project of Longevity and Aging in Dujangyan, WMH white matter hyperintensities
aMean age (range, if available, or ± if standard deviation) in years at baseline, unless stated otherwise; bMedian age (interquartile range, IQR) in years; cMinimal
and maximum mean age in years of the studies referred to; dMedian age (range) in years
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ii) To test the relationship between hallmarks of aging
and cognitive impairment in the oldest-old.
iii) To test the relationship between markers of
neurodegeneration and cognitive impairment in the
oldest-old.




We aimed to include 80 cognitively normal subjects and
40 subjects with cognitive impairment, both aged 90
years and older. Inclusion criteria for cognitively normal
subjects were a global Clinical Dementia Rating (CDR)
score of 0 [62] and a score ≥ 26 points on the Mini--
Mental State Examination (MMSE) [63]. Inclusion criteria
for subjects with cognitive impairment were a diagnosis of
amnestic MCI (aMCI) [64] or a diagnosis of probable or
possible AD [65] by a neurologist, geriatrician, or general
practitioner, a global CDR score ≥ 0.5 point (s) and a
MMSE score of 20–28 points (inclusive). Exclusion cri-
teria were the physical inability to undergo the proce-
dures, visual or hearing impairment which made
neuropsychological testing impossible, severe depression
(Geriatric Depression Scale (GDS) score ≥ 11 points [66])
and other comorbidities or medication that could impair
cognition at the discretion of the investigator (e.g. stroke,
epilepsy or use of lithium carbonate). During the inclusion
period it turned out to be difficult to identify subjects of
90 years and older with aMCI or probable or possible AD;
we therefore broadened the inclusion criteria in this group
to subjects older than 85 years.
Subjects were recruited at two sites: the Amsterdam
UMC, The Netherlands and The University of Manches-
ter, United Kingdom. Cognitively normal subjects were
recruited from general practitioners or via advertise-
ments (Amsterdam) or from the Manchester and
Newcastle Ageing Study (MNAS, Manchester). Subjects
with cognitive impairment were only recruited in the
Netherlands. They were recruited from the Alzheimer
Center Amsterdam and the Center Of Geriatric medi-
cine Amsterdam (COGA) at the Amsterdam UMC, geri-
atric departments of other hospitals in the surroundings
of Amsterdam, other healthcare facilities (such as a care
home), general practitioners or via advertisement. The
sample collection started on the 1st of June 2016 and
ended on the 30th of June 2018. Currently we are work-
ing on the first data analyses.
The Medical Ethics Review Committee of the Amsterdam
UMC approved the study in Amsterdam and the National
Research Ethics Service Committee North West - Greater
Manchester South performed approval of the study in Man-
chester. The study was carried out in accordance with the
ethical conduct and juridical laws of the Declaration of
Helsinki 64th WMA General Assembly, Fortaleza, Brazil,
October 2013, (www.wma.net), and in accordance with the
Medical Research Involving Human Subjects Act (WMO).
All subjects gave written informed consent.
Study design
The EMIF-AD 90+ Study is a case-control study in
which we search for protective factors for cognitive im-
pairment. Therefore, the cognitively normal subjects are
described as cases and the subjects with cognitive im-
pairment as controls.
Study procedures
The study consisted of two home visits and one or two
visits at the hospital/clinical research facility (CRF). Dur-
ing the first home visit, in- and exclusion criteria
(MMSE, CDR, impression of physical ability to undergo
the procedures, hearing and visual abilities) were
verified, in addition to collection of first study data
(Table 3, paragraphs 2.3.1, 2.3.2 and 2.3.4). The MMSE
is a short cognitive screening test with a maximum score
of 30 points [63]. The CDR is a scale for the severity of
symptoms of dementia, which was assessed by
interviews with the subject and, if available, study part-
ner (somebody that is in regular contact with the sub-
ject) in combination with judgement by the researchers
[62]. The second home visit consisted of a neuropsycho-
logical assessment performed by a neuropsychologist
(paragraph 2.3.3). During the hospital/CRF visits several
procedures were performed, which are listed in Table 3
and described in paragraphs 2.3.4. – 2.3.10. These proce-
dures provided information on i) potential protective
factors (classified in six different domains), ii) hallmarks
of aging, and iii) markers of neurodegeneration (Fig. 1
and Table 3). For each domain, hallmark of aging or
markers of neurodegeneration, we will test one or more
parameters (Table 3). In most cases, all procedures were
performed within three months from start of the in-
clusion. Any differences in study procedures between
Amsterdam and Manchester are explicitly stated in
this paper.
Interview
Data about the medical and family history, medication use,
education and intoxications (alcohol use and smoking)
were collected through a structured interview, in combin-
ation with information provided by the study partner (if
available), general practitioner and/or medical specialist.
Questionnaires
In Amsterdam, subjects were asked to complete six
questionnaires. Activities of daily living (ADL) were eval-
uated by use of the Katz ADL [67]. Functional health
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and wellbeing were evaluated by the Short form-12
Health-related Quality of Life (SF-12 HRQoL) question-
naire [68] and by the Cognitive Complaints Index (CCI)
[69]. Nutrition was evaluated by the Mini Nutritional
Assessment (MNA-long version) [70]. Sleep disorders
were evaluated by use of the Berlin Questionnaire which
identifies the risk of sleep disordered breathing [71].
Cognitive activity during life, such as reading books and
playing games, was assessed with the cognitive abilities
questionnaire [72]. Subjects with cognitive impairment
filled in the questionnaires together with a study partner.
The GDS was filled in together with the researcher [66].
Table 3 The domains of interest in the EMIF-AD 90+ Study




Cognitive reserve Level of education Interview Home Home
Cognitive activity Cognitive abilities questionnaire Home Home
Vascular comorbidity Cholesterol level, hypertension, DM, stroke, AF Blood collection Hospital WMIC
Medical history and medication use Home Home
Blood pressure Hospital CRF
Diagnostick/heart rate Home CRF
Ultrasound carotid artery Hospital CRF
Mood and sleep Depressive symptoms Geriatric Depression Scale Home Home
Sleep disorder Berlin Questionnaire and MSQ Home Home
Accelerometer (sleep quality) Home N/A
Sensory system Visual acuity ETDRS chart Hospital N/A
Retinal thickness OCT Hospital N/A
Auditory function Digits-in-noise test Home N/A
Olfactory function Sniffin sticks Hospital N/A
Physical performance
and capacity
Physical performance Grip strength Home CRF
Short Physical Performance Battery
or 4-min walking test
Hospital CRF
BIA (muscle mass) Hospital N/A
Physical activity Accelerometer Home N/A
Genetics APOEε4 and APOEε2 Blood collection Hospital WMIC
Hallmarks of ageing Level of inflammation markers Blood collection (i.a. PBMCs) Hospital WMIC
Level of senescence markers Skin biopsy (senescence markers p16,
p53 and telomere associated foci)
Hospital N/A
Nutritional status BIA Hospital N/A





Aβ1–42 and tau in CSF and blood CSF collection
Blood collection
Hospital N/A
Amyloid PET scan Amyloid PET scan Hospital WMIC
Brain atrophy Brain MRI scan or brain CT scan Hospital CRF
WMH Brain MRI scan or brain CT scan Hospital CRF
White matter integrity Brain MRI scan Hospital N/A
Brain connectivity Brain MRI scan Hospital CRF
MEG Hospital N/A
Aβ Amyloid β, AD Alzheimer’s disease, AF atrial fibrillation, APOE Apolipoprotein E, BIA Bioelectrical impedance analysis, BMI Body Mass Index, CRF Clinical Research
Facility, CT Computerized Tomography, CSF cerebrospinal fluid, DM diabetes mellitus, ETDRS Early Treatment Diabetic Retinopathy Study, MEG magnetoencephalography,
MNA Mini Nutritional Assessment, MRI Magnetic Resonance Imaging, MSQ Mayo Sleep Questionnaire, N/A not applicable, OCT Optical Coherence Tomography, PBMCs
Peripheral Blood Mononuclear Cells, PET positron emission tomography, PLAD Project of Longevity and Aging in Dujangyan, WMH white matter hyperintensities, WMIC
Wolfson Molecular Imaging Centre
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In Amsterdam, the study partner was asked to
complete five questionnaires: the AD8 (an 8-question
test for the study partner to assess mild dementia) [73],
the Amsterdam instrumental Activities of Daily Living
(iADL) scale (a study partner based tool aimed at detect-
ing iADL problems in early dementia) [74, 75], the
Neuropsychiatric Inventory Questionnaire (NPI-Q, to
assess the severity of behavioral symptoms in the subject
and the distress these symptoms cause in the study part-
ner) [76], the Mayo Sleep Questionnaire (MSQ, to
screen for the presence of Rapid Eye Movement (REM)
sleep disorders) [77], and finally the CCI [69].
In Manchester, subjects were asked to complete the
SF-12 HRQoL questionnaire [68], the Physical Activity
Scale for the Elderly (PASE) [78], the CCI [69] and the
cognitive abilities questionnaire [72]. The study partner
was asked to complete the AD8 [73], the Functional Ac-
tivities Questionnaire (FAQ) [79] and the CCI [69].
Neuropsychological assessment
The neuropsychological assessment took approximately
one and a half hours during which several cognitive do-
mains were tested. Table 4 gives an overview of the dif-
ferent cognitive tests that were administered, which
domain they examine and at which site they were
performed.
Physical examination
In Amsterdam, data on waist and hip circumference
(cm), and hand grip strength (kg), as well as a standard
neurologic screening examination were recorded during
the first home visit. Hand grip strength was measured to
estimate muscle strength and was performed with a
hand dynamometer (Jamar hand dynamometer; Sam-
mons Preston, Inc., Bolingbrook, IL., USA) [80]. In
addition, a ‘Diagnostick’ was used to determine whether
the subject had atrial fibrillation by measuring one de-
rivative of an electrocardiogram [81]. At the end of the
first home visit, the subject was asked to wear an accel-
erometer (DynaPort MoveMonitor, McRoberts B.V., The
Hague, The Netherlands) for seven days to measure
physical activity and sleep quality.
During the hospital visit in Amsterdam, continuous
blood pressure measurements were performed
non-invasively using a digital photoplethysmogram on
the right middle finger (Nexfin®, BMEYE, Amsterdam,
The Netherlands), resulting in beat-to-beat BP data. The
Short Physical Performance Battery (SPPB) included bal-
ance tests, a 4 m walk to measure walking speed and the
chair stand test [82]. Body composition, including the
Body Mass Index (BMI), was measured using a Bioelec-
trical Impedance Analysis (BIA; InBody 770; Biospace
Co., Ltd., Seoul, Korea).
In Manchester, waist and hip circumference (cm),
hand grip strength (kg), BMI, resting blood pressure,
heart rate, ankle/brachial pressure index [83] and a 4
min walking test were recorded at the clinical research
facility.
Sensory system
Measurements of the sensory system were only per-
formed in Amsterdam. With regard to visual function-
ing, best corrected visual acuity was tested with an Early
Treatment Diabetic Retinopathy Study (ETDRS) chart.
Intra-Ocular Pressure (IOP) and refraction data of all
subjects were obtained, and all subjects underwent slit
lamp examination and indirect fundoscopy. Pupils were
dilated using tropicamide 0.5% and phenylephrine 5%.
Peripapillary Retinal Nerve Fiber Layer (pRNFL) thick-
ness and macular (layer) thickness were measured with
Spectral Domain Optical Coherence Tomography
(SD-OCT, Heidelberg Spectralis) using Heidelberg’s
build-in software [84]. With enhanced depth imaging,
Fig. 1 Overview of the domains of interest in the EMIF-AD 90+ Study. Aβ Amyloid β, CSF cerebrospinal fluid, PET positron emission tomography
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the choroid was imaged and its thickness was (manually)
measured. With fundus photography (Topcon TRC
50DX type IA), we acquired digital fundus images (50°).
From these, seven Retinal Vascular Parameters (RVPs)
were obtained using Singapore I Vessel Assessment
(SIVA, version 3.0) [85].
For the auditory function, we used the digits-in-noise
(DIN) test [86]. The DIN test is a speech-in-noise test
using digit triplets as speech material. The digit triplets
are presented against a constant level of stationary back-
ground noise. The test uses an adaptive procedure to de-
termine the signal-to-noise ratio at which a listener
understands 50% of the digit triplets correctly (i.e. the
speech reception threshold (SRT) in noise). Olfactory
function was measured using “Sniffin’ Sticks” (Burghart,
Wedel, Germany). The test consists of pen-like odor dis-
pensing devices with odors that are considered to be
familiar. The smell test in the present study contained
the odor identification part of the test [87].
Blood collection and skin biopsy
In both centers, blood samples were collected according
to the biobanking pre-analytical Standard Operating
Procedures (SOPs) of the Biomarkers for Alzheimer’s
disease and Parkinson’s disease (BIOMARKAPD) project
[88]. Blood samples were collected for DNA and RNA
analysis, inflammation markers, proteomics, neurode-
generative markers (amyloid β, tau, neurofilament light),
routine blood analysis (i.e. lipids and glucose), vitamin
status (B12 and folic acid) and, in Amsterdam only, for
Peripheral Blood Mononuclear Cells (PBMCs). Planned
DNA analysis includes Single Nucleotide Polymorphisms
(SNP) analysis of known genetic risk factors for AD or
amyloid pathology [89–92]. DNA and RNA isolation will
Table 4 Cognitive tests in the EMIF-AD 90+ Study
Cognitive test Cognitive domain Site
CERAD 10 words test [115]
Immediate recall
Delayed recall after 10 min
Memory Ba
Logical Memory test [116]
Immediate recall
Delayed recall after 20–30min
Memory A
Rey Auditory Verbal Learning Test [117]
Immediate recall
Delayed recall after 20 min
Memory M
Rey Complex Figure Test [118]
Copy




WAIS-III Digit span forward and backward [119, 120] Executive functioning B
Animal (2 min) and Letter fluency (1 min per letterb) [121] Executive functioning B
Clock Drawing Testc [122] Executive functioning
Visuospatial functioning
A
Graded Naming Test [123] Object-naming ability B




WAIS-R Digit Symbol Substitution Test [125] Perceptual-motor speed
Incidental learning
B




National Adult Reading Test [127] Pre-morbid IQ B
Visual Association Test [128] Visuospatial association learning A






A administered only in Amsterdam, B administered in Amsterdam and Manchester, CERAD Consortium to Establish a Registry for Alzheimer’s Disease, M administered
only in Manchester, min minute (s), WAIS (−R) Wechsler Adult Intelligence Scale (-Revised)
aIn Manchester only in the cognitively normal subjects. bIn Amsterdam using the letters D, A and T and in Manchester the letters F, A, and S. cThe subject will be
asked to draw a clock showing the time “ten after eleven”. In total 14 points can be scored based on the presence and sequencing of the numbers and the
positioning of the two hands
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be performed by EMIF-AD partners. Remaining samples
will be stored for future biomarker identification and
validation studies.
In Amsterdam, four millimeter skin biopsies were
taken from the inner upper medial arm and will be
stained for senescence markers p16, p53 and telomere
associated foci.
Cerebrospinal fluid collection
In Amsterdam, up to 20 mL CSF was obtained by lum-
bar puncture in Sarstedt polypropylene syringes using a
Spinocan 25 Gauge needle in one of the intervertebral
spaces between L3 and S1. A half mL CSF was immedi-
ately processed for leukocyte count, erythrocyte count,
glucose, and total protein. The remaining CSF was
mixed and centrifuged at 1300–2000 × g at 4 °C for ten
minutes. Supernatants were stored in aliquots of 0.25–
0.5 mL and frozen within two hours at − 80 °C and
stored for future biomarker discovery studies. The pro-
cessing and storing of CSF was performed according to
the BIOMARKAPD SOP [88]. Amyloid β 1–42, total tau
and phosphorylated tau 181 will be analyzed in a single
batch. Remaining samples will be stored for future bio-
marker identification and validation studies.
Ultrasound carotid artery
At both sites, a duplex ultrasound scan of the carotid ar-
tery was performed. In Amsterdam, the right carotid ar-
tery was scanned to assess intima media thickness and
distension using ArtLab software [93, 94]. In Manches-
ter, left and right carotid arteries were scanned to deter-
mine velocity, vessel thickness, stenosis and plaques,
rated according to the North American Symptomatic
Carotid Endarterectomy Trial guidelines [95].
Brain MRI scan
Subjects underwent locally optimized brain MRI protocols
including 3D-T1, fluid attenuated inversion recovery
(FLAIR), susceptibility weighted imaging (SWI), diffusion
tensor imaging (DTI) and resting state functional MRI
(rs-fMRI). MRI scans were performed on Philips 3 T
Achieva scanners. Additionally, in Manchester regional
cerebral blood flow was measured by arterial spin labelling
[96], but no DTI scan was acquired in Manchester. In
Amsterdam, if a subject could not undergo the MRI scan,
we considered a CT scan (Philips Ingenuity TF or Gemini
TF camera). Scans will be analyzed locally and centrally by
EMIF-AD partners using the Neugrid infrastructure if ap-
plicable (see Additional file 1).
Amyloid PET scan
[18F] Flutemetamol, a specific fibrillary amyloid β radio-
tracer, was used for the amyloid PET scans. In
Amsterdam, [18F] flutemetamol was produced by General
Electric (GE) Healthcare at the Cyclotron Research Center
of the University of Liège (Liège, Belgium) and PET scans
were performed using a Philips Ingenuity TF PET-MRI
scanner (Philips Medical Systems, Cleveland, Ohio, USA)
or, in case of a PET-CT scan, the Philips Ingenuity TF
(Philips Medical Systems, Best, the Netherlands) or Gem-
ini TF scanner (Philips Medical Systems, Best, the
Netherlands). In Manchester, [18F] flutemetamol was pro-
duced at the Wolfson Molecular Imaging Centre
(WMIC)‘s Good Manufacturing Practice radiochemistry
facility using GE Healthcare’s FASTlab and cassettes and
PET scans were performed using a High Resolution Re-
search Tomograph (HRRT; Siemens/CTI, Knoxville, TN).
In both centers, the emission scan was performed in two
parts. First a 30min dynamic emission scan was started
simultaneously with a bolus intravenous injection of 185
MBq [18F] flutemetamol. The second part of the scan was
performed from 90 to 110min post injection. In
Amsterdam, immediately before each part of the PET scan
a T1-weighted gradient echo pulse MRI or low dose CT
scan was obtained. This MRI or CT scan was used for at-
tenuation correction of the PET scan. In Manchester, two
seven minute transmission scans, one before the first
emission scan and the other after the second emission
scan, using a 137Cs point source were acquired for subse-
quent attenuation and scatter correction.
All [18F] flutemetamol scans were read visually as posi-
tive or negative. Additionally, we determined time activity
curves for each region of interest with cerebellum grey
matter as input function [97]. The dynamic data were ana-
lyzed on a voxel-by-voxel level using the Simplified Refer-
ence Tissue Model 2 (SRTM2) [98, 99]. Finally, we
investigated tracer uptake by using a simplified method:
the standardized uptake value ratio (SUVr, target to grey
matter cerebellum SUV over 90–110min pi) [100]. Vari-
ability in acquisition of amyloid PET scans were reduced
by harmonizing acquisition protocols and will be reduced
by adding it to the analyses as a covariate.
Neurophysiology
In Amsterdam, MEG was performed using a 306 chan-
nel whole-head system (Elekta Neuromag Oy, Helsinki,
Finland). Eyes-closed and eyes-open resting-state MEG
data were recorded with subjects in supine position in-
side a magnetically shielded room. We will use trans-
formed time series [101] to extract spectral properties
(relative band power and peak frequency) [102], and es-
timates of functional connectivity between brain regions,
and metrics that characterize the topology of the func-
tional brain networks [103, 104]. These analyses will be
applied using Elekta’s beamformer software, and both
in-house developed Matlab tools and BrainWave soft-
ware (http://home.kpn.nl/stam7883/brainwave.html).
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Planned statistical analyses
For each parameter listed in Table 3, we will test with lo-
gistic regression models whether it is associated with re-
silience to cognitive impairment. In addition, linear
regression models will be used to associate the same pa-
rameters with cognitive functioning in the total sample.
Potential additional analyses include the identification of
protective factors for abnormal AD biomarkers in the
subsample of cognitively normal subjects and the identi-
fication of protective factors for cognitive impairment in
subjects with a high risk, for example APOE ε4 carriers.
Discussion
We described the design of the EMIF-AD 90+ Study
that aims to unravel the factors associated with resilience
to cognitive impairment in the oldest-old. An important
additional value of the EMIF-AD 90+ Study compared
to the previous studies is the extensive phenotyping of
subjects, which includes data about cognitive reserve,
vascular comorbidities, mood, sleep, sensory system cap-
acity, physical performance and capacity and genetic risk
factors. Furthermore, the EMIF-AD 90+ Study is one of
the first studies that collects a broad range of markers of
neurodegeneration in the oldest-old, including an amyl-
oid PET scan, amyloid β and tau measured in CSF and
blood and neurophysiological measures.
The EMIF-AD 90+ is the first study worldwide that
combines data regarding the hallmarks of aging with
markers of neurodegeneration. The process of aging and
the incidence of aMCI and possible or probable AD are
very much interrelated. Our study allows to test hypoth-
eses such as that common risk factors and pathways
drive both the aging process and development of cogni-
tive impairment or AD. Another strength of the
EMIF-AD 90+ study is that we use objective measures
wherever possible, instead of using questionnaires. For
example, physical activity and sleep quality were mea-
sured with an accelerometer in Amsterdam.
To conclude, the results of the EMIF-AD 90+ Study
will provide an important contribution to the existing
literature in many different ways. It will extend our
knowledge on protective factors for cognitive impair-
ment in the oldest-old and will determine how hallmarks
of aging and markers of neurodegeneration relate to
cognitive impairment in this specific age group.
Additional file
Additional file 1: Table S1. Brain MRI scan analyses in the EMIF-AD 90+
Study. (DOCX 26 kb)
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